MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
GeoVax Labs Market Cap 2011-2026 | GOVX
As of January 10, 2026 GeoVax Labs has a market cap of $ 309 K
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap GeoVax Labs
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.72 M | 758 K | 10.8 M | 6.47 M | 39.3 K | 4.16 M | 3.08 M | 2.54 M | 2.4 M | 5.73 T | 10.4 T | 12.8 T | 13.7 T |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.7 T | 39.3 K | 3.28 T |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
4.09 M | $ 1.06 | -0.93 % | $ 5.78 M |  China |
 |
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.82 | -4.85 % | $ 464 M |  Britain |
 |
Adagene
ADAG
|
87.8 M | $ 1.65 | - | $ 92.9 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.45 | 3.6 % | $ 8.3 B |  Australia |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.25 B | $ 64.9 | -0.15 % | $ 8.68 B |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Biogen
BIIB
|
19.3 B | $ 187.4 | 0.75 % | $ 27.3 B | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
BioXcel Therapeutics
BTAI
|
5.37 M | $ 1.98 | -1.0 % | $ 5.02 M | USA |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
CASI Pharmaceuticals
CASI
|
1.09 B | $ 1.04 | -2.34 % | $ 142 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Biosciences
CBIO
|
33.6 M | $ 10.74 | -2.1 % | $ 707 M | USA |
 |
Legend Biotech Corporation
LEGN
|
11.2 B | $ 23.58 | 2.39 % | $ 18.7 B | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.31 M | $ 27.0 | -1.28 % | $ 1.74 M | USA |
 |
Cellectis S.A.
CLLS
|
203 M | $ 4.42 | -1.34 % | $ 116 M | France |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 201.94 | -3.26 % | $ 5 B |  Danmark |
 |
BioVie
BIVI
|
2.44 M | $ 1.27 | -2.31 % | $ 1.88 M | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
62.9 B | $ 99.81 | 0.97 % | $ 27.2 B | Germany |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 27.75 | 0.02 % | $ 1.34 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 4.14 | -3.72 % | $ 9.01 B |  Israel |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 11.13 | -2.02 % | $ 720 M | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
Axon Enterprise
AXON
|
39.8 B | $ 633.45 | 3.34 % | $ 48 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.64 | -0.75 % | $ 16.6 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AstraZeneca PLC
AZN
|
81.2 B | $ 94.65 | 0.68 % | $ 96.9 B | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | USA |